Filtered By:
Drug: Avastin
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 6276 results found since Jan 2013.
Silicone oil droplets in repackaged anti-vascular endothelial growth factors for intravitreal injections: In search of the main source of contamination.
CONCLUSION:: 0.5 mL insulin syringes with staked-in needles used for supplying the product seem to be the main source of silicone oil contamination in repackaged anti-vascular endothelial growth factors. Silicone-free insulin syringes with staked-in needles would be strongly recommended for supplying anti-vascular endothelial growth factor intravitreal injections from compounding pharmacies.
PMID: 30642195 [PubMed - as supplied by publisher]
Source: European Journal of Ophthalmology - January 15, 2019 Category: Opthalmology Authors: Olea JL, Gómez-Resa M, Cervera-Peris MM, Aragón JA Tags: Eur J Ophthalmol Source Type: research
Anti-vascular endothelial growth factor for neovascular glaucoma.
CONCLUSIONS: Currently available evidence is uncertain regarding the long-term effectiveness of anti-VEGF medications, such as intravitreal ranibizumab or bevacizumab or aflibercept, as an adjunct to conventional treatment in lowering IOP in NVG. More research is needed to investigate the long-term effect of these medications compared with, or in addition to, conventional surgical or medical treatment in lowering IOP in NVG.
PMID: 32027392 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - February 5, 2020 Category: General Medicine Authors: Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB Tags: Cochrane Database Syst Rev Source Type: research
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer
CONCLUSIONS: We found low-certainty evidence in favour of the use of bevacizumab plus chemotherapy. However, bevacizumab probably increases specific adverse events (gastrointestinal perforations or fistulae, thromboembolic events, hypertension) and serious adverse events. We found low-certainty evidence that does not support the use of cediranib plus chemotherapy, apatinib plus chemotherapy, apatinib plus chemotherapy/brachytherapy, or pazopanib monotherapy. We found low-certainty evidence suggesting that pazopanib plus lapatinib worsens outcomes. The VEGF inhibitors apatinib and pazopanib may increase the probability of h...
Source: Cochrane Database of Systematic Reviews - March 4, 2021 Category: General Medicine Authors: Yunhai Chuai Ivana Rizzuto Xia Zhang Ying Li Guanghai Dai Sophie J Otter Rasiah Bharathan Alexandra Stewart Aiming Wang Source Type: research
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
CONCLUSIONS: There was very low or low quality evidence from RCTs for the efficacy and safety of anti-VEGF agents when used to treat PDR over and above current standard treatments. However, the results suggest that anti-VEGFs can reduce the risk of intraocular bleeding in people with PDR. Further carefully designed clinical trials should be able to improve this evidence.
PMID: 25418485 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 24, 2014 Category: Journals (General) Authors: Martinez-Zapata MJ, Martí-Carvajal AJ, Solà I, Pijoán JI, Buil-Calvo JA, Cordero JA, Evans JR Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy.
CONCLUSIONS: The use of pre- or intraoperative bevacizumab lowers the incidence of early POVCH. The reported complications from its use appear to be low. Futher randomised studies that look at other anti-VEGF medications are ongoing and will strengthen the current review findings, giving both surgeons and patients evidence to guide treatment choices in the management of proliferative retinopathy.
PMID: 26250103 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - August 7, 2015 Category: Journals (General) Authors: Smith JM, Steel DH Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema.
CONCLUSIONS: Combination of intravitreal anti-VEGF plus intravitreal steroids does not appear to offer additional visual benefit compared with monotherapy for DMO; at present the evidence for this is of low-certainty. There was an increased rate of cataract development and raised intraocular pressure in eyes treated with anti-VEGF plus steroid versus anti-VEGF alone. Patients were exposed to potential side effects of both these agents without reported additional benefit. The majority of the evidence comes from studies of bevacizumab and triamcinolone used as primary therapy for DMO. There is limited evidence from studies u...
Source: Cochrane Database of Systematic Reviews - April 18, 2018 Category: General Medicine Authors: Mehta H, Hennings C, Gillies MC, Nguyen V, Campain A, Fraser-Bell S Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor for proliferative diabetic retinopathy
CONCLUSIONS: Anti-VEGFs ± PRP compared with PRP alone probably increase visual acuity, but the degree of improvement is not clinically meaningful. Regarding secondary outcomes, anti-VEGFs ± PRP produce a regression of new vessels, reduce vitreous haemorrhage, and may reduce the need for vitrectomy compared with eyes that received PRP alone. We do not know if anti-VEGFs ± PRP have an impact on the incidence of adverse events and they may have little or no effect on patients' quality of life. Carefully designed and conducted clinical trials are required, assessing the optimal schedule of anti-VEGFs alone compared with PRP...
Source: Cochrane Database of Systematic Reviews - March 20, 2023 Category: General Medicine Authors: Maria Jos é Martinez-Zapata Ignacio Salvador Arturo J Mart í-Carvajal Jos é I Pijoan Jos é A Cordero Dmitry Ponomarev Ashleigh Kernohan Ivan Sol à Gianni Virgili Source Type: research
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
CONCLUSIONS: The results of this review indicate the effectiveness of anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of maintaining visual acuity; ranibizumab and bevacizumab were also shown to improve visual acuity. The information available on the adverse effects of each medication do not suggest a higher incidence of potentially vision-threatening complications with intravitreal injection compared with control interventions; however, clinical trial sample sizes may not have been sufficient to detect rare safety outcomes. Research evaluating variable dosing regimens with anti-VEGF agents, effects of...
Source: Cochrane Database of Systematic Reviews - September 4, 2014 Category: Journals (General) Authors: Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor for diabetic macular oedema.
CONCLUSIONS: There is high quality evidence that antiangiogenic drugs provide a benefit compared to current therapeutic options for DMO, that is grid laser photocoagulation, in clinical trial populations at one or two years. Future research should investigate differences between drugs, effectiveness under real-world monitoring and treatment conditions, and safety in high-risk populations, particularly regarding cardiovascular risk.
PMID: 25342124 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - October 24, 2014 Category: Journals (General) Authors: Virgili G, Parravano M, Menchini F, Evans JR Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.
CONCLUSIONS: The evidence is currently of low quality which is insufficient to refute or support anti-VEGF subconjunctival injection for control of wound healing in glaucoma surgery. The effect on IOP control of anti-VEGF agents in glaucoma patients undergoing trabeculectomy is still uncertain, compared to MMC.Further RCTs of anti-VEGF subconjunctival injection in glaucoma surgery are required, particularly compared to sham treatment with at least 12 months follow-up.
PMID: 26769010 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - January 15, 2016 Category: Journals (General) Authors: Cheng JW, Cheng SW, Wei RL, Lu GC Tags: Cochrane Database Syst Rev Source Type: research
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
CONCLUSIONS: Results of this review show the effectiveness of anti-VEGF agents (pegaptanib, ranibizumab, and bevacizumab) in terms of maintaining visual acuity; studies show that ranibizumab and bevacizumab improved visual acuity in some eyes that received these agents and were equally effective. Available information on the adverse effects of each medication does not suggest a higher incidence of potentially vision-threatening complications with intravitreous injection of anti-VEGF agents compared with control interventions; however, clinical trial sample sizes were not sufficient to estimate differences in rare safety ou...
Source: Cochrane Database of Systematic Reviews - March 3, 2019 Category: General Medicine Authors: Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS Tags: Cochrane Database Syst Rev Source Type: research
Histological changes secondary to use of anti-angiogenic therapy after interruption of vasa vasorum flow in the descending aorta: results in a porcine model
Conclusions The medication exhibited a trend toward reduced angiogenesis and injury, but no reduction in the inflammatory process or intimal thickening of the aortic wall. These findings are in disagreement with studies that correlate neovascularization with increased migration of inflammatory cells. Bevacizumab exhibited toxicity in the porcine model.Resumo Contexto Agentes antiangiog ênicos podem ter implicações terapêuticas na progressão e manifestação da aterosclerose. Objetivos Demonstrar a alteração histológica secundária ao uso de bevacizumabe na aorta descendente de suínos submetida à interrupção dos...
Source: Jornal Vascular Brasileiro - April 26, 2019 Category: Surgery Source Type: research
Quantifying the increasing use of anti-vascular endothelial growth factor therapy in ophthalmology
CONCLUSION: Bevacizumab is one of the most far reaching drugs in ophthalmology and even medicine, but it is not yet supported by high quality evidence. The much higher cost of ranibizumab may be responsible for bevacizumab's popularity among eye specialists. Patients should be fully informed about the off-label use of bevacizumab and the associated risks with its use.PMID:22815647 | PMC:PMC3399721
Source: McGill Journal of Medicine : MJM - July 21, 2012 Category: Universities & Medical Training Authors: Jonathan A Micieli Andrew Micieli Source Type: research
